Abstract
The aim of this prospective, randomized study was to compare the effects of tigecycline and imipenem-cilastatin on fibrinogen levels in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients were empirically randomized to receive tigecycline or imipenem-cilastatin. Fibrinogen levels were measured in both patient groups on days 1, 3, 5 and 8 of antibiotic therapy and 3 days after antibiotic therapy completion. Twenty patients received tigecycline and 22 patients received imipenem-cilastatin . Patients in the tigecycline group had lower mean fibrinogen levels compared to those in the imipenem-cilastatin group on day 3 (4.1 +/- 1.2 vs. 5.9 +/- 1.3 g/L; p < 0.001), day 5 (3.7 +/- 1.2 vs. 6.5 +/- 1.1 g/L; p < 0.001), day 8 (3.5 +/- 1.3 vs. 5.8 +/- 1.6 g/L; p < 0.001), and day 3 after antibiotic completion (4.1 +/- 1.4 vs. 6.1 +/- 1.6 g/L; p < 0.001). In conclusion, compared to imipenem-cilastatin, tigecycline was associated with a significant decrease in fibrinogen levels, following CRS and HIPEC.